Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The denosumab and zoledronic acid groups were comparable at baseline, with no significant differences in age, sex distribution, BMI, serum calcium and phosphorus levels, BMD at any site, BTMs, eGFR, 25-hydroxyvitamin D, parathyroid hormone (PTH), prevalence of prior fractures, tobacco and alcohol use, or 10-year FRAX scores (P > 0.05 for all), indicating that the groups were well-matched (Table 1).

Source: Baseline characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Denosumab versus zoledronic acid for primary osteoporosis: a 36-month retrospective cohort study on bone mineral density changes

Source: Article title.

This single-center, retrospective cohort study included patients diagnosed with osteoporosis at the First Affiliated Hospital of Guangxi University of Science and Technology between January 2021 and January 2023, patients were enrolled between January 2021 and January 2023.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Denosumab versus zoledronic acid for primary osteoporosis: a 36-month retrospective cohort study on bone mineral density changes

Cohort study · Frontiers in Medicine · 2026

Original publication title

Denosumab versus zoledronic acid for primary osteoporosis: a 36-month retrospective cohort study on bone mineral density changes

Xin Zou; Xiaomeng Huang; Mingxin Tang; Yuyan Zhu; Cheng Li; Liangjun Zhao

Copyright © 2026 Zou, Huang, Tang, Zhu, Li and Zhao.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Over 36 months, both agents were effective. Denosumab was associated with greater BMD gains, stronger bone resorption suppression, and fewer recorded adverse reactions. These findings are hypothesis-generating and await prospective validation.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To explore and compare the clinical efficacy and safety of denosumab versus zoledronic acid for the treatment of primary osteoporosis.

Source: Objective

Abstract: What methods does the paper describe?

This retrospective cohort study included 413 primary osteoporosis patients (denosumab, n = 198; zoledronic acid, n = 215). All received daily calcium (600 mg) and vitamin D (400 IU), representing the total combined daily intake from diet and supplements. The denosumab group received subcutaneous denosumab 60 mg every 6 months and the zoledronic acid group annual intravenous zoledronic acid 5 mg over 36 months. Outcomes assessed at baseline and after 36 months included bone mineral density (BMD) at the lumbar spine, femoral neck, and total hip; bone turnover markers β-CTX (β-isomerized C-terminal telopeptide of type I collagen) and P1NP (procollagen type I N-terminal propeptide); pain severity using the Visual Analog Scale (VAS); functional impairment using the Oswestry Disability Index (ODI); and incidence of adverse reactions.

Source: Methods

Abstract: Results

After 36 months, BMD at all sites significantly increased from baseline in both groups (P < 0.001). The denosumab group demonstrated greater mean absolute increases in BMD at the lumbar spine (0.13 ± 0.10 vs. 0.10 ± 0.10 g/cm2, P < 0.001), femoral neck (0.14 ± 0.06 vs. 0.12 ± 0.05 g/cm2, P < 0.001), and total hip (0.09 ± 0.12 vs. 0.05 ± 0.09 g/cm2, P < 0.001) compared to the zoledronic acid group.

Both groups showed significant decreases in β-CTX and P1NP levels (P < 0.001), with the denosumab group exhibiting a greater reduction in β-CTX (−0.54 ± 0.47 vs. −0.34 ± 0.44 ng/mL, P < 0.001) and P1NP (−23.68 ± 5.44 vs. −19.98 ± 5.28 ng/mL, P < 0.001). VAS and ODI scores improved significantly in both groups (P < 0.001), with a greater reduction in the VAS score in the denosumab group (−5.17 ± 1.58 vs. −4.61 ± 1.48, P < 0.001).

The overall incidence of adverse reactions was lower in the denosumab group compared to the zoledronic acid group (5.56% vs. 20.00%, P = 0.008). Adverse events were collected via passive EMR retrieval (see Methods).

Source: Results

Abstract: Conclusion

Over 36 months, both agents were effective. Denosumab was associated with greater BMD gains, stronger bone resorption suppression, and fewer recorded adverse reactions. These findings are hypothesis-generating and await prospective validation.

Source: Conclusion
Authors’ abstract

Objective

To explore and compare the clinical efficacy and safety of denosumab versus zoledronic acid for the treatment of primary osteoporosis.

Methods

This retrospective cohort study included 413 primary osteoporosis patients (denosumab, n = 198; zoledronic acid, n = 215). All received daily calcium (600 mg) and vitamin D (400 IU), representing the total combined daily intake from diet and supplements. The denosumab group received subcutaneous denosumab 60 mg every 6 months and the zoledronic acid group annual intravenous zoledronic acid 5 mg over 36 months. Outcomes assessed at baseline and after 36 months included bone mineral density (BMD) at the lumbar spine, femoral neck, and total hip; bone turnover markers β-CTX (β-isomerized C-terminal telopeptide of type I collagen) and P1NP (procollagen type I N-terminal propeptide); pain severity using the Visual Analog Scale (VAS); functional impairment using the Oswestry Disability Index (ODI); and incidence of adverse reactions.

Results

After 36 months, BMD at all sites significantly increased from baseline in both groups (P < 0.001). The denosumab group demonstrated greater mean absolute increases in BMD at the lumbar spine (0.13 ± 0.10 vs. 0.10 ± 0.10 g/cm2, P < 0.001), femoral neck (0.14 ± 0.06 vs. 0.12 ± 0.05 g/cm2, P < 0.001), and total hip (0.09 ± 0.12 vs. 0.05 ± 0.09 g/cm2, P < 0.001) compared to the zoledronic acid group.

Both groups showed significant decreases in β-CTX and P1NP levels (P < 0.001), with the denosumab group exhibiting a greater reduction in β-CTX (−0.54 ± 0.47 vs. −0.34 ± 0.44 ng/mL, P < 0.001) and P1NP (−23.68 ± 5.44 vs. −19.98 ± 5.28 ng/mL, P < 0.001). VAS and ODI scores improved significantly in both groups (P < 0.001), with a greater reduction in the VAS score in the denosumab group (−5.17 ± 1.58 vs. −4.61 ± 1.48, P < 0.001).

The overall incidence of adverse reactions was lower in the denosumab group compared to the zoledronic acid group (5.56% vs. 20.00%, P = 0.008). Adverse events were collected via passive EMR retrieval (see Methods).

Conclusion

Over 36 months, both agents were effective. Denosumab was associated with greater BMD gains, stronger bone resorption suppression, and fewer recorded adverse reactions. These findings are hypothesis-generating and await prospective validation.

Publication and source details

Original title: Denosumab versus zoledronic acid for primary osteoporosis: a 36-month retrospective cohort study on bone mineral density changes

Xin Zou; Xiaomeng Huang; Mingxin Tang; Yuyan Zhu; Cheng Li; Liangjun Zhao

Frontiers in Medicine · 2026

* Correspondence: Liangjun Zhao, zhaoliangjun163@163.com
†

These authors share first authorship

Copyright © 2026 Zou, Huang, Tang, Zhu, Li and Zhao.2026Zou, Huang, Tang, Zhu, Li and Zhaohttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Middle/Young Aged Teachers’ Research Ability Improvement Project of Guangxi Higher Education (Grant No. 2024KY0129), Guangxi Natural Science Foundation (2024GXNSFAA010446), and the Scientific Research Foundation of Guangxi Administration of Traditional Chinese Medicine (GXZYB20220328). There is no actual or potential conflict of interest including financial, personal or other relationships with other people or organizations.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:02:02.455621+00:00

DOI: 10.3389/fmed.2026.1842793 · PMC13461511